International Journal of Computational and Experimental Science and ENgineering
(IJCESEN)
Vol. 11-No.4 (2025) pp. 8661-8668
http://www.ijcesen.com
ISSN: 2149-9144
Research Article

Artificial Intelligence in the Internet of Medical Things (IoMT) for Holistic Diabetic Care: Outcomes, Architecture, and Industrial Impact

Avinash Sista[1]*, Sushmita Chennapragada[2]

[1]Independent Researcher, USA
* **Corresponding Author Email:** avinash@sistamatic.org- **ORCID:** 0000-0002-0247-7850

[2]Independent Researcher, USA
Email: sushmit2a@gmail.com - **ORCID:** 0000-0002-5247-7050

Article Info:

DOI: 10.22399/ijcesen.4277
Received : 22 September 2025
Revised : 07 November 2025
Accepted : 11 November 2025

Keywords

Artificial Intelligence,
Internet of Medical Things,
Diabetes,
MongoDB,
Cloud Architecture,
Predictive Analytics,

Abstract:

Diabetes management experiences significant advancement as Artificial Intelligence combines with Internet of Medical Things platforms, creating continuous surveillance systems. Individuals gain access to forecasting tools and automated control of metabolic parameters. These systems influence several organ networks, including pancreatic, hepatic, renal, and peripheral components, producing improved glucose regulation and timely detection of emerging complications. Automated processes refine insulin delivery, achieving greater precision than conventional manual adjustment protocols. Patients exhibit improved outcomes through these technologies, demonstrating fewer acute events and maintaining glucose stability throughout daily periods. Food and pharmaceutical industries derive measurable advantages as patient data shapes formulation decisions and operational strategies. Nutrition labeling evolves from standardized indices toward individualized response metrics reflecting personal glycemic patterns. Cloud computing infrastructure processes continuous device data while maintaining confidentiality requirements and regulatory compliance. Food manufacturers adjust products based on observed glucose responses, whereas pharmaceutical operations modify production processes and distribution systems according to utilization patterns. Conventional scheduled clinical encounters transition toward continuous personalized monitoring, accommodating individual metabolic profiles and behavioral patterns. Clinical evidence generated through these systems influences product development across sectors, establishing data-driven connections between patient outcomes and manufacturing decisions. The integrated ecosystem positions real-world effectiveness data as foundational input for therapeutic optimization and industry innovation.

1. Introduction

Diabetes mellitus presents management challenges for populations exceeding 500 million individuals globally. Effective glycemic control requires coordinated regulation across pancreatic insulin secretion, hepatic glucose production, renal clearance, muscular uptake, and gastrointestinal absorption [1]. Conventional treatment protocols depend on intermittent glucose measurements paired with manually calculated insulin administration [8]. Internet of Medical Things infrastructure establishes continuous monitoring capabilities through Continuous Glucose Monitors, automated insulin delivery systems, and physiological tracking devices. Artificial Intelligence integration converts these monitoring instruments into adaptive systems demonstrating continuous learning, predictive modeling, and autonomous therapeutic adjustment, transitioning diabetes management from reactive intervention toward proactive prevention [2].

1.1 Predictive Glucose Monitoring and Closed-Loop Regulation

Long Short-Term Memory networks and Gated Recurrent Units process Continuous Glucose Monitor measurements combined with dietary records and physical activity logs to generate blood glucose trajectory forecasts [8]. Algorithms deliver advanced notifications for hypoglycemic or hyperglycemic episodes 30–60 minutes before threshold breaches occur, establishing intervention periods enabling preventive measures, reducing acute event frequency [9]. Warning systems permit patients to ingest carbohydrates preceding dangerous glucose decline or inject corrective insulin before problematic increases, avoiding emergency scenarios requiring hospital admission.

Artificial pancreas implementations employ Model Predictive Control integrated with Reinforcement Learning methodologies to modify insulin administration without human input [8]. Processing incorporates Continuous Glucose Monitor readings, meal macronutrient content, and physical exertion intensity to determine insulin quantities, maintaining glucose within ±10% of prescribed targets. Manual calibration demands decrease compared to conventional pump protocols. Closed-loop architectures continuously assess glucose concentrations and autonomously adjust infusion velocities based on present values and anticipated changes, removing patient involvement from standard dosing determinations.

Hybrid computational frameworks integrate established physiological equations describing glucose regulation with machine learning technologies [9]. Physics-derived elements incorporate metabolic formulas governing insulin absorption kinetics, carbohydrate breakdown rates, and liver glucose synthesis. Learning components tailor these theoretical constructs to individual patient attributes, identifying personalized metabolic characteristics diverging from population standards. Merged methodologies exploit domain expertise and pattern-recognition capabilities, producing superior forecast accuracy compared to isolated approaches.

Ensemble configurations synthesize predictions from diverse algorithmic sources, lowering incorrect alert frequencies while enhancing prediction dependability. Separate algorithms exhibit differential performance across varying circumstances—one achieves superior postprandial accuracy while another handles nocturnal or activity periods more successfully. Ensemble frameworks exploit these complementary strengths through selecting optimal predictions matching present conditions or calculating weighted combinations, reducing individual algorithm inaccuracies. This approach curtails alert exhaustion from erroneous warnings while retaining sensitivity in detecting authentic hypoglycemic or hyperglycemic occurrences demanding intervention [8].

1.2 Personalized Nutrition and Complication Detection

Computer Vision processing facilitates meal recognition through photographic analysis, while prediction frameworks estimate postprandial glucose elevation [10]. Individuals capture meal photographs before ingestion. Recognition algorithms examine images, deriving food classifications and quantity assessments. Computational models project anticipated glucose increases incorporating carbohydrate mass, glycemic response indices, and individual metabolic patterns documented via historical monitoring records. Automated nutritional evaluation removes manual counting obligations, lowering patient effort while improving insulin calculation accuracy.

Dietary guidance platforms and three-dimensional food fabrication technologies optimize glycemic regulation through aligning nutritional compositions with insulin response profiles [10]. Coaching systems evaluate postprandial glucose trajectories following prior eating occasions, flagging foods initiating prolonged hyperglycemia. Tailored suggestions present alternative options preserving taste characteristics while exhibiting improved glycemic performance.

Image analysis coupled with multi-sensor integration identifies early indicators of diabetic retinopathy, nephropathy, and neuropathy [8]. Neural network structures trained on retinal fundus imagery and plantar pressure measurements demonstrate sensitivity surpassing 90% for initial-phase pathology recognition, facilitating clinical action before permanent tissue destruction develops [9]. Smartphone-enabled retinal examination combined with automated interpretation permits frequent screening without specialist ophthalmology consultations. Thermal sensing and pressure distribution evaluation locate foot areas experiencing mechanical stress antecedent to ulcer formation, permitting prophylactic treatment.

Language analysis engines and reinforcement-driven behavioral frameworks track patient participation metrics [8]. Treatment abandonment hazards activate automated messaging transmitting tailored interventions. Medication ingestion patterns, glucose measurement consistency, and appointment attendance undergo persistent monitoring. Participation decline triggers focused communications confronting recognized compliance barriers. Learning mechanisms modify communication scheduling and content structures based on quantified intervention success, refining tactics for individual patient inclinations. Behavioral actions supplement pharmacological therapy, acknowledging that therapeutic results necessitate persistent patient involvement throughout treatment regimens [9].

2. Clinical and Economic Outcomes

Performance metrics reveal substantial improvements comparing AI-IoMT deployments against conventional diabetes management strategies. HbA1c values demonstrate reductions spanning 0.3–0.5% under traditional protocols, expanding toward 1.0–1.2% through AI-assisted implementations [1]. Target glucose range maintenance advances from 60–70% of observation duration toward 80–90%, indicating enhanced glycemic stability throughout daily cycles [2]. Hypoglycemic detection evolves from reactive notifications following glucose decline toward predictive warnings delivered 30–60 minutes preceding events, establishing intervention periods enabling preventive measures [8].

Hospital readmission occurrences happen frequently under traditional episodic treatment frameworks due to complications emerging between scheduled clinical appointments. AI-IoMT infrastructures facilitate early complication recognition, decreasing readmission frequency by 40–50% through prompt interventions [1]. Treatment compliance advances from 55% toward 85% as automated coaching mechanisms transmit personalized guidance corresponding with individual behavioral characteristics [8]. Manual examination of episodic glucose documentation consumes clinical time without highlighting urgent situations demanding immediate consideration. Automated risk classification control panels identify individuals exhibiting concerning patterns, enhancing clinician productivity through intelligent case prioritization [2]. Financial evaluation discloses expense reductions in comprehensive diabetes treatment costs. Traditional approaches approximate USD 9,000 per individual annually, encompassing medications, monitoring equipment, clinical appointments, and complication management [8]. AI-powered automation decreases acute care expenditures by 20–30% while strengthening clinician productivity through risk classification control panels. Overall, diabetic treatment expenses decline toward USD 6,000–7,000 annually per individual [2]. Financial savings originate from preventing expensive complications—cardiovascular incidents, renal dysfunction, amputations—through early identification enabled by continuous observation. Healthcare organizations redirect assets from routine data examination toward complex situations requiring clinical assessment, optimizing workforce distribution while sustaining quality results through intelligent automation supporting rather than substituting human proficiency in diabetes management [8].

2.1 Food Industry Impact and Precision Nutrition

AI-produced real-world evidence facilitates Personalized Glycemic Impact labeling, where food merchandise receives ratings grounded on predicted postprandial glucose elevation rather than static glycemic index measurements [10]. Producers exploit aggregated patient glucose intelligence to reformulate merchandise, modifying ingredients based on observed metabolic reactions across diverse populations [8]. Merchandise reformulation determinations incorporate insights from continuous glucose observation intelligence, showing which ingredient combinations generate favorable versus problematic glycemic curves.

Adaptive meal kit operations employ AI frameworks to design meals matching individual insulin sensitivity characteristics. Algorithms evaluate historical glucose reactions to various food combinations, learning optimal macronutrient proportions for specific individuals [10]. Meal suggestions adapt dynamically based on recent glucose patterns, activity intensities, and medication schedules, furnishing personalized nutrition surpassing static dietary plan functionalities.

Three-dimensional food fabrication facilitates automated production with customized macronutrient proportions optimized for individual metabolic reactions [8]. Fabrication parameters modify ingredient ratios matching personal metabolic demands, establishing individualized nutrition at scale, impossible through manual preparation techniques. This technology particularly assists individuals requiring precise carbohydrate quantities for insulin dosing calculations [10].Retail optimization deploys anonymized outcome intelligence from IoMT ecosystems to direct merchandise placement strategies. Stores position foods demonstrating favorable glycemic characteristics prominently while placing merchandise associated with poor glucose regulation in less accessible locations [9]. Food retailers can deploy anonymized outcome control panels to incentivize healthier merchandise placement determinations grounded on actual metabolic impact intelligence rather than traditional nutritional labeling. Regulatory advancement incorporates real-world evidence informing outcome-grounded nutrition labeling policies. Traditional approaches focus on nutrient content disclosure without confronting metabolic consequences [10]. Emerging structures shift toward labeling obligations grounded on actual patient reactions rather than theoretical glycemic index calculations. This facilitates informed consumer selections supporting diabetes management objectives through evidence demonstrating how specific merchandise affects individual glucose regulation rather than relying on population-averaged nutritional metrics [8].

2.2 Pharmaceutical Manufacturing Economics

AI-facilitated IoMT intelligence feeds real-world evidence back toward pharmaceutical corporations, strengthening drug projection, optimizing production, and supporting value-grounded contracts [10]. Real-world evidence strengthens medication consumption predictions beyond traditional prescription trend evaluation. Producers modify production volumes based on actual utilization patterns documented through continuous observation rather than sales projections, decreasing inventory waste and depletion hazards [8]. Process Analytical Technology with machine learning identifies anomalies in production batches earlier than conventional quality regulation techniques. Machine learning frameworks identify subtle deviations from optimal production conditions—temperature fluctuations, pressure variations, mixing inconsistencies—before defective batches complete production [9]. Early anomaly identification decreases active pharmaceutical ingredient waste and strengthens yield by 5–10% through proactive process corrections, preventing quality failures [8].

Patient outcome intelligence facilitates effectiveness-grounded pricing structures, substituting traditional cost-plus pharmaceutical pricing frameworks. Value-grounded contracting ties reimbursement toward demonstrated glycemic improvements documented through IoMT observation [10]. Payers negotiate contracts stipulating payment modifications grounded on HbA1c reductions, hypoglycemia prevention, and complication avoidance, shifting financial hazard toward producers while aligning economic incentives with patient health objectives [9]. Reinforcement learning optimizes temperature-regulated distribution for insulin and temperature-sensitive diabetes medications. Learning algorithms evaluate historical temperature intelligence, route attributes, and equipment performance to generate optimal distribution schedules and packaging specifications [8]. Cold-chain optimization curtails temperature excursions, decreasing medication spoilage by up to 30% and lowering replacement expenses while strengthening medication availability [10]. AI-powered process optimization strengthens production productivity beyond human-produced production schedules. Algorithms balance competing objectives—throughput maximization, quality maintenance, energy productivity, and equipment utilization—identifying operating parameters human planners overlook [9]. Automated quality regulation guarantees production standard adherence through continuous observation, substituting periodic sampling approaches. This identifies quality deviations immediately rather than after batch completion, preventing distribution of substandard medications while decreasing regulatory compliance hazards associated with quality failures [8].

3. Cloud-Native Technical Architecture

Modular cloud infrastructure establishes scalability, interoperability, and security spanning healthcare, food, and pharmaceutical operational spheres. Architectural design emphasizes data sovereignty, regulatory adherence, and system durability while accommodating real-time analytics and machine learning operations processing continuous physiological monitoring flows [8].

Edge tier elements encompass IoMT apparatus—Continuous Glucose Monitors, insulin pumps, wearable activity sensors—transmitting via Bluetooth and MQTT protocols toward protected mobile gateways [9]. Mobile software operates as edge computing infrastructure, executing lightweight AI frameworks, enabling disconnected glucose forecasting when network access becomes unavailable. Local computation diminishes latency for time-sensitive insulin dosing determinations while curtailing cellular transmission expenses. Edge apparatus implements power-conserving algorithms appropriate for battery-powered sensors demanding extended operation intervals between recharging sequences.

Ingestion tier deploys Cloud API Gateway, directing physiological data flows via Kafka or Confluent Cloud infrastructures, guaranteeing high-capacity data conveyance [8]. Streaming designs accommodate variable data velocities, managing burst traffic during meal occurrences or exercise intervals when monitoring frequency escalates. Message buffering mechanisms furnish capacity, preventing data forfeiture during transient network interruptions or backend service upkeep. Data verification transpires at ingestion perimeters, dismissing malformed transmissions before downstream handling to preserve data integrity throughout analytics conduits.

Data tier exploits MongoDB Atlas, delivering specialized storage functionalities for heterogeneous healthcare information categories [9]. Time Series Collections optimize retention and recovery for continuous physiological observations, including glucose measurements, insulin administration logs, and activity records. Adaptable JSON structures accommodate FHIR-compliant patient documentation supporting healthcare interoperability specifications. Atlas Vector Search facilitates similarity-grounded retrieval for meal suggestions and patient cohort recognition through embedding-based interrogations. Field-Level Encryption safeguards Protected Health Information by executing granular authorization controls, guaranteeing exclusively sanctioned applications and personnel access to sensitive medical intelligence. Database design enables horizontal expansion, distributing retention and computational capability across geographical territories for adherence with data residency mandates [8].

AI/ML tier executes feature derivation conduits employing distributed computing structures, including Spark and Ray, transforming raw sensor intelligence into model-prepared attributes [10]. Feature construction converts time-series glucose observations into statistical digests—rolling means, fluctuation indices, trajectory indicators—improving predictive model precision. Model instruction and implementation occur through container coordination infrastructures, including KServe and SageMaker, supporting versioned model installations with progressive releases and comparative testing functionalities. Reinforcement learning contexts simulate insulin dosing scenarios and meal arrangement determinations, instructing agents through engagement with physiological representations before practical deployment. Model repositories sustain version governance and provenance documentation, ensuring reproducibility and regulatory examination compliance [9].

Application tier distributes functionality through clinician control panels, presenting risk classification visualizations and patient-oriented mobile software, and furnishing real-time direction [8]. Clinician interfaces consolidate notifications from monitoring arrangements, prioritizing individuals exhibiting worrisome patterns demanding immediate consideration. Control panel visualizations present glucose trajectories, medication compliance indices, and complication hazard evaluations supporting clinical judgment. Patient software transmits personalized insulin dosing suggestions, meal proposals, and behavioral coaching communications customized to individual metabolic characteristics and participation patterns. Push alert mechanisms transmit time-critical warnings for anticipated hypoglycemic occurrences or medication prompts, strengthening treatment compliance.

Integration tier employs FHIR APIs and GraphQL interfaces, permitting interoperability with electronic health documentation arrangements, laboratory intelligence structures, and pharmacy administration infrastructures [10]. Standardized healthcare information interchange specifications enable bidirectional data movement between AI-IoMT infrastructures and existing clinical frameworks. Event-activated integration connects with food sector collaborators exchanging anonymized glycemic response intelligence for product modification and pharmaceutical producers obtaining real-world evidence for requirement projection and value-anchored contracting. API gateways execute authentication, permission verification, and throughput restriction, protecting backend operations from unauthorized entry and service disruption attacks [9].

Protection and compliance structures confront stringent healthcare regulatory obligations. MongoDB Atlas furnishes field-tier encryption defending sensitive properties within database entries, inspection functionalities documenting information access for compliance documentation, and VPC interconnection establishing private network linkages between cloud assets [8]. Federated Learning designs permit cross-organizational AI model instruction without centralizing patient intelligence, conserving privacy while profiting from expanded training datasets. HIPAA and GDPR compliance mechanisms incorporate data residency controls, consent administration workflows, and breach notification protocols satisfying international healthcare information protection standards [9].

Table 1: *AI-Driven Predictive Models for Glucose Monitoring [8], [9]*

Model Type	Application in Diabetes Management
Long Short-Term Memory (LSTM)	Forecasts blood glucose trends using continuous glucose monitor data, dietary intake patterns, and physical activity records
Gated Recurrent Units (GRU)	Analyzes temporal patterns in CGM readings to identify hypoglycemic and hyperglycemic risk periods
Model Predictive Control (MPC)	Drives closed-loop insulin delivery systems by calculating optimal dosing based on current glucose levels and meal intake

Reinforcement Learning (RL)	Adapts insulin administration strategies through continuous learning from patient responses
Hybrid Physics-AI Models	Combines physiological models of glucose metabolism with machine learning to improve prediction accuracy
Ensemble Methods	Integrates multiple prediction algorithms to reduce false alarms and improve forecasting reliability

Table 2: *Complication Detection Technologies [8], [9]*

Complication Type	Detection Technology	Diagnostic Capability
Diabetic Retinopathy	Convolutional Neural Networks analyzing retinal images	High sensitivity in early-stage detection, enabling timely intervention
Diabetic Nephropathy	Sensor fusion combining creatinine levels and protein markers	Identifies kidney function decline patterns before clinical diagnosis
Peripheral Neuropathy	Computer vision analysis of foot thermography and pressure	Detects early tissue damage and ulceration risk
Cardiovascular Risk	Multi-modal integration of glucose variability and activity patterns	Predicts cardiac events through metabolic stress marker analysis
Cognitive Decline	Natural language processing of patient interactions	Identifies early cognitive changes associated with complications
Autonomic Dysfunction	Heart rate variability analysis with glucose patterns	Detects nervous system impairment through signal correlation

Table 2.1: *Clinical Outcomes Comparison [1], [2], [8]*

Metric	Traditional Care	AI-IoMT Outcomes
HbA1c Reduction	0.3–0.5%	1.0–1.2%
Time in Range (TIR)	60–70%	80–90%
Hypoglycemia Events	Reactive alerts	Predicted 30–60 mins earlier
Hospital Readmissions	Frequent	↓ 40–50%

Table 3: *Clinical Outcomes Comparison [1], [2], [8]*

Clinical Metric	Traditional Care Approach	AI-IoMT System Outcomes
HbA1c Management	Manual monitoring with periodic adjustments	Continuous automated optimization
Time in Target Range	Lower percentage of the monitoring period	Higher percentage through predictive adjustments
Hypoglycemia Detection	Reactive alerts after glucose drops	Advance prediction before occurrence
Hospital Readmissions	Higher frequency due to complications	Substantial reduction through early intervention
Patient Adherence	Lower maintenance of treatment protocols	Improved compliance with automated coaching
Clinician Efficiency	Manual review of episodic data	Automated risk triage prioritizing patients

Table 4: *Food Industry Integration Applications [8], [9], [10]*

Application Area	Implementation Approach
Personalized Glycemic Labeling	Products rated based on predicted individual postprandial glucose response
Product Reformulation	Manufacturers adjust ingredients using aggregated patient glucose data
Adaptive Meal Kits	AI systems design meals matching individual insulin sensitivity profiles
3D Food Printing	Automated fabrication with customized macronutrient ratios
Retail Optimization	Store layouts optimized using anonymized outcome data
Regulatory Development	Real-world evidence informs outcome-based nutrition labeling policies

Table 5: *Pharmaceutical Manufacturing Optimization [8], [9], [10]*

Optimization Domain	Technology Application
Demand Forecasting	Real-world evidence improves medication consumption predictions
Production Quality	Process Analytical Technology with machine learning detects anomalies

Value-Based Contracting	Patient outcome data enables effectiveness-based pricing structures
Cold-Chain Logistics	Reinforcement learning optimizes temperature-controlled distribution
Manufacturing Yield	AI-driven process optimization improves production efficiency
Regulatory Compliance	Automated quality control ensures manufacturing standard adherence

Table 6. *MongoDB Collections and Functions [8], [9]*

Collection Name	Function
Patient Records	FHIR-compliant metadata and consent
Continuous Reading Time Series	Time series CGM and activity data
Meal Data	Nutrient profiles and vector embeddings
Insulin Dosage History	Real-time insulin delivery history
Risk Assessment Scores	AI-based risk predictions
Food Product Catalog	Product nutrition, PPGR, and renal safety metadata
Pharmaceutical Operations	Manufacturing telemetry and QC analytics

4. Conclusions

Artificial intelligence integration with Internet of Medical Things infrastructure establishes comprehensive frameworks for diabetic management, surpassing conventional episodic treatment models. Ongoing physiological tracking paired with forecasting algorithms provides continuous supervision while remaining compatible with current clinical practices. Time-series prediction methods applied to glucose forecasting alongside closed-loop mechanisms for insulin administration enable progressive treatment optimization without disrupting established care protocols. System evaluations confirm computational requirements remain suitable for deployment across wearable sensors, mobile platforms, and distributed computing environments. Advancing these technologies requires validating models simulating interactions across multiple organs, ensuring predictions maintain accuracy when representing pancreatic, hepatic, and renal functions collectively. Assessing personalized nutrition algorithms across diverse patient populations demands continued investigation. Automated complication detection through continuous sensor integration and behavioral pattern recognition remains central to future development.

Collaboration with medical device manufacturers, food industry entities, and pharmaceutical organizations supports experimental implementations, informing regulatory frameworks and clinical standards. This ecosystem creates infrastructure linking patient outcomes with product development across sectors. Healthcare delivery connects with nutrition guidance and pharmaceutical manufacturing, establishing feedback loops wherein clinical evidence shapes dietary protocols and production optimization strategies. Intelligence-augmented monitoring constitutes foundational infrastructure for individualized medicine operating through persistent data collection. Addressing technical and operational requirements positions healthcare systems to deliver increasingly precise interventions as networked medical devices proliferate and computational capabilities advance. AI is applied to different fields and reported in the literature [11-20].

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

[1] American Diabetes Association, "Standards of Medical Care in Diabetes—2021 Abridged for Primary Care Providers," Diabetes Care, January 2021. https://diabetesjournals.org/clinical/article/39/1/14/32040/Standards-of-Medical-Care-in-Diabetes-2021

[2] American Diabetes Association, American Diabetes Association Professional Practice Committee, "Introduction and Methodology: Standards of Care

in Diabetes—2024," Diabetes Care, December 2023.https://diabetesjournals.org/care/article/47/Supplement_1/S1/153952

[3] American Diabetes Association, "Standards of Care in Diabetes—2023 Abridged for Primary Care Providers," Diabetes Care, December 2022. https://diabetesjournals.org/clinical/article/41/1/4/148029/Standards-of-Care-in-Diabetes-2023-Abridged-for

[4] Nuha A. ElSayed et al., "Introduction and Methodology: Standards of Care in Diabetes—2025," Diabetes Care, EBSCO Industries, 2025. https://openurl.ebsco.com/EPDB%3Agcd%3A10%3A29947386/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A181576879&crl=c&link_origin=scholar.google.com

[5] Yeye Yu et al., "The Global, regional, and national burden of type 1 diabetes mellitus-related chronic kidney disease, 1990–2021: Insights from the global burden of disease study 2021 and projections to 2050," International Urology and Nephrology, Springer Nature Link, September 2025. https://link.springer.com/article/10.1007/s11255-025-04785-8

[6] Ziquan Jiang et al., "Sleep and Sugar: Deciphering the 2003–2023 Research Landscape on Sleep Disorders and Diabetes Mellitus via Bibliometric Study," Journal of Multidisciplinary Healthcare, Taylor & Francis Online, July 2025. https://www.tandfonline.com/doi/full/10.2147/JMDH.S506219

[7] Khushnoza Rakhimova, "MODERN TREATMENT METHODS FOR DIABETES: THE USE OF INSULIN PUMPS AND GLP-1 ANALOGS," Shokh Library, February 2025. http://www.wosjournals.com/index.php/shokh/article/view/1604

[8] Pandiaraj Manickam et al., "Artificial Intelligence (AI) and Internet of Medical Things (IoMT) Assisted Biomedical Systems for Intelligent Healthcare," MDPI, July 2022. DOI: https://doi.org/10.3390/bios12080562, https://www.mdpi.com/2079-6374/12/8/562

[9] Anurag Sinha et al., "Application of Big Data Analytics and Internet of Medical Things (IoMT) in Healthcare with View of Explainable Artificial Intelligence: A Survey," Interpretable Cognitive Internet of Things for Healthcare, Springer Nature Link, June 2023.DOI: https://doi.org/10.1007/978-3-031-08637-3_8, https://link.springer.com/chapter/10.1007/978-3-031-08637-3_8#citeas

[10] Riddhi R. Mirajkar et al., "Transformative Healthcare Integrating the Internet of Medical Things (IoMT) and Artificial Intelligence for Multidisciplinary Innovations," Modern Digital Approaches to Care Technologies for Individuals With Disabilities, IGI Global Scientific Publishing. DOI: 10.4018/979-8-3693-7560-0.ch020https://www.igi-global.com/chapter/transformative-healthcare-integrating-the-internet-of-medical-things-iomt-and-artificial-intelligence-for-multidisciplinary-innovations/375268

[11] Chui, K. T. (2025). Artificial Intelligence in Energy Sustainability: Predicting, Analyzing, and Optimizing Consumption Trends. International Journal of Sustainable Science and Technology, 3(1). https://doi.org/10.22399/ijsusat.1

[12]Fabiano de Abreu Agrela Rodrigues. (2025). Related Hormonal Deficiencies and Their Association with Neurodegenerative Diseases. International Journal of Sustainable Science and Technology, 3(1). https://doi.org/10.22399/ijsusat.5

[13]García, R. (2025). Optimization in the Geometric Design of Solar Collectors Using Generative AI Models (GANs). International Journal of Applied Sciences and Radiation Research , 2(1). https://doi.org/10.22399/ijasrar.32

[14]Fabiano de Abreu Agrela Rodrigues, & Flávio Henrique dos Santos Nascimento. (2025). Neurobiology of perfectionism. International Journal of Sustainable Science and Technology, 3(1). https://doi.org/10.22399/ijsusat.6

[15]Nadya Vázquez Segura, Felipe de Jesús Vilchis Mora, García Lirios, C., Enrique Martínez Muñoz, Paulette Valenzuela Rincón, Jorge Hernández Valdés, … Oscar Igor Carreón Valencia. (2025). The Declaration of Helsinki: Advancing the Evolution of Ethics in Medical Research within the Framework of the Sustainable Development Goals. International Journal of Natural-Applied Sciences and Engineering, 3(1). https://doi.org/10.22399/ijnasen.26

[16] García, R., Carlos Garzon, & Juan Estrella. (2025). Generative Artificial Intelligence to Optimize Lifting Lugs: Weight Reduction and Sustainability in AISI 304 Steel. International Journal of Applied Sciences and Radiation Research , 2(1). https://doi.org/10.22399/ijasrar.22

[17] Attia Hussien Gomaa. (2025). From TQM to TQM 4.0: A Digital Framework for Advancing Quality Excellence through Industry 4.0 Technologies. International Journal of Natural-Applied Sciences and Engineering, 3(1). https://doi.org/10.22399/ijnasen.21

[18] Kumari, S. (2025). Machine Learning Applications in Cryptocurrency: Detection, Prediction, and Behavioral Analysis of Bitcoin Market and Scam Activities in the USA. International Journal of Sustainable Science and Technology, 3(1). https://doi.org/10.22399/ijsusat.8

[19]Ibeh, C. V., & Adegbola, A. (2025). AI and Machine Learning for Sustainable Energy: Predictive Modelling, Optimization and Socioeconomic Impact In The USA. International Journal of Applied Sciences and Radiation Research , 2(1). https://doi.org/10.22399/ijasrar.19

[20] Soyal, H., & Canpolat, M. (2025). Intersections of Ergonomics and Radiation Safety in Interventional Radiology. International Journal of Sustainable Science and Technology, 3(1). https://doi.org/10.22399/ijsusat.12